NCT04699110View on ClinicalTrials.gov

Adrenaline for the Treatment of No-Reflow in Normotensive Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Acute Coronary SyndromeNo-Reflow PhenomenonNormotensive
Interventions
DRUG

Adrenaline

Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow

DRUG

Adenosine

Control group will receive adenosine (100 to 400 mcg)

Trial Locations (1)

Unknown

National Institute of Cardiovascular Diseases, Karachi

All Listed Sponsors
lead

National Institute of Cardiovascular Diseases, Pakistan

OTHER

NCT04699110 - Adrenaline for the Treatment of No-Reflow in Normotensive Patients | Biotech Hunter | Biotech Hunter